A012303: ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Title
- ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Principal Investigator
- Safi, Danish
- Phase
- III (Cancer Control)
- Age Group
- Adult
- Applicable Disease Sites
- Breast Cancer
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Sabrina Rexroad, RN
- Research Nurse
- Email: sabrina.rexroad1@wvumedicine.org
- Valli White, RN
- Research Nurse
- Phone: +1 304-264-1220
- Email: valli.white@wvumedicine.org
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org
- Nnennaya Opara
- Clinical Research Specialist
- Phone: +1 681-342-1000
- Email: nnennaya.opara1@wvumedicine.org